A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy
of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc fusion protein injection
(Yisaipu®) in the treatment of peripheral enthesitis in active axial spondyloarthritis(SpA)
patients.